Meet-the-Expert Sessions

Biomarker Selection of Non-Small Cell Lung Cancer Patients for Initial Therapy
Paul A. Bunn, Jr., University of Colorado Health Sciences Center, Aurora, CO

Cell-Cell Adhesion in Development and Cancer
Ann Marie Pendergast, Duke University Medical Center, Durham, NC

Development, Validation, Interpretation and Clinical Implementation of Statistical Models for Familial Risk Prediction
Giovanni Parmigiani, Johns Hopkins University, Baltimore, MD

Diet, Nutrition, and Cancer: The Search for Truth
Walter C. Willett, Harvard School of Public Health, Boston, MA

Investigating Rearrangements in Human Cancer
P. Andrew Futreal, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Mitochondria and Apoptosis: Stepping Stones on the Road to Ruin
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN

Novel Strategies in the Therapy of HER2-Positive Breast Cancer
José Baselga, Vall d’Hebron University Hospital, Barcelona, Spain

PI3 Kinase in Tumors of the Nervous System
William A. Weiss, University of California, San Francisco, CA

Proteomics and Mass Spectrometry: Applications to Cancer Research
Natalie G. Ahn, University of Colorado, Boulder, CO

TGFβ: The Good, the Bad, and the Surprising
Mary Helen Barcellos-Hoff, New York University Langone School of Medicine, New York, NY

The Hypoxic Microenvironment: Inflammation and Tumor Progression
Randall S. Johnson, University of California, San Diego, La Jolla, CA

Using Mouse Models to Understand p53
Laura D. Attardi, Stanford University School of Medicine, Stanford, CA

Control of Gene Therapy by Ionizing Radiation: Basic Principles to Clinical Trials
Ralph R. Weichselbaum, The University of Chicago, Chicago, IL

Drug Discovery in the p53 Pathway
David P. Lane, Institute of Molecular and Cell Biology, Singapore

Sequencing a Cancer Genome
Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Achieving the Potential of Chemoprevention
Frank L. Meyskens, Jr., University of California, Orange, CA

Cancer-related Inflammation
Frances R. Balkwill, Barts and The London School of Medicine and Dentistry, London, United Kingdom

Correlating Histology and Tissue Proteomics Using Mass Spectrometry in Cancer Research
Richard M. Caprioli, Vanderbilt University, Nashville, TN

Dissecting the Cancer Epigenome for Its Constituents, Origins, Contributions to Tumorigenesis, and Translational Implications
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

HSP90 Inhibitors and Beyond: New Ways of Targeting the Molecular Chaperone
Paul Workman, Cancer Research UK, Sutton, United Kingdom

Immunologic Biomarkers: Measuring Immune Stimulation and Suppression
Mary L. Disis, University of Washington, Seattle, WA

Regulation of Growth by the mTOR Pathway
David M. Sabatini, The Whitehead Institute for Biomedical Research, Cambridge, MA

T Cell Antigen Recognition and Tolerance
Philippa Marrack, Howard Hughes Medical Institute, Denver, CO

The Influence of the Tumor Microenvironment on Drug Response and Drug Resistance
William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Translational Implications of Colon Cancer Genetics
Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH

Tumor Microenvironment Controls the Rate of Cancer Progression and Metastasis
Raghu Kalluri, Beth Israel Deaconess Medical Center, Boston, MA

Why Development Compounds Fail, and What Industry Is Doing to Increase Success Rates
John T. Hunt, Bristol-Myers Squibb Company, Princeton, NJ

Building the Bridge between the Laboratory and the Clinic for Novel Immunotherapies in Chronic Lymphocytic Leukemia
John C. Byrd, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Conducting a Successful International Consortium to Conduct Epidemiologic Research in Gliomas
Melissa L. Bondy, UT M. D. Anderson Cancer Center, Houston, TX

DNA Damage Responses: From Molecular Mechanism to Clinical Intervention
Michael B. Kastan, St. Jude Children’s Research Hospital, Memphis, TN

Inflammation-Regulated EMT in the Pathogenesis of Lung Cancer
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA

Mechanism-Based Combination Therapy: Combining ERK and PI3K/AKT Inhibitors
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

Mechanistic Discovery in Murine Cancer Models: From Basic Discovery to Clinical Translation
Terry A. Van Dyke, National Cancer Institute, Frederick, MD

Mutant ras in Cancer: Biologic Insights and Therapeutic Potential
Kevin M. Shannon, University of California, San Francisco, CA

The Role of Endogenously Expressed Prosurvival Bcl-2 Family Members in Tumor Development and Sustaining Tumor Growth
Andreas Strasser, The Walter and Eliza Hall Institute, Parkville, Australia

Translating Cancer Biology into Cancer Medicine: IGFIR Ab Development in Sarcomas
Lee J. Helman, National Cancer Institute, Bethesda, MD

Utilization of DNA Markers in New Models and Primary Tumors for Targeted Therapies
David Sidransky, Johns Hopkins Medical Institutes, Baltimore, MD

Breast Cancer Treatment by Molecular Insights: How Diverse Can We Make It?
Laura J. van’t Veer, University of California Comprehensive Cancer Center, San Francisco, CA

Inflammation and Cancer
Mariano Barbacid, National Cancer Center of Spain (CNIO), Madrid, Spain

Normal and Neoplastic Stem Cells
Irving L. Weissman, Stanford University School of Medicine, Palo Alto, CA

Cancer Epigenomics in Chronic Lymphocytic Leukemia
Christoph Plass, German Cancer Research Center, Heidelberg, Germany

Cross-Talk of Innate Resistance and Immunity
Giorgio Trinchieri, National Cancer Institute, Frederick, MD

Genomic and Proteomic Changes Induced by the Tumor Microenvironment that Regulate Metastasis
Amato J. Giaccia, Stanford University School of Medicine, Stanford, CA

Mouse Models for Mesothelioma and Lung Cancer
Anton J. M. Berns, The Netherlands Cancer Institute, Amsterdam, Netherlands

New Synthetic Triterpenoids and Rexinoids: Applications and Mechanisms for Cancer Prevention and Treatment
Michael B. Sporn, Dartmouth Medical School, Hanover, NH

Selective and Mechanistic Factors that Contribute to Recurrent Oncogenic Translocations
Frederick W. Alt, Children’s Hospital Boston, Boston, MA

Targeting DNA Repair Pathways in Cancer Therapy
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA

Targeting the ras Pathway
Frank McCormick, University of California Comprehensive Cancer Center, San Francisco, CA

The Origins of Breast Cancer Heterogeneity: The Role of the Cellular Hierarchy and Genetics, and the Microenvironment
Charlotte Kuperwasser, Tufts University School of Medicine, Boston, MA